More drugs have high sensitivities for BC patients in cluster 2, including AZD.2281(Olaparib), AZD6244(Selumetinib), Bosutinib, CGP.60474(PKC inhibitor), CI.1040 (MEK inhibitor), Etoposide, GDC.0449(Vismodegib), Gefitinib, Gemcitabine, JNK.9L (JNK inhibitor), Pyrimethamine, Roscovitine, and Temsirolimus. Here, MAPK8 is linked to breast cancer.